Novartis Ag (NVS) Current Deferred Revenue (2017 - 2020)

Novartis Ag's Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $56.0 million for Q4 2020.

• In Q4 2020, Current Deferred Revenue fell 50.88% year-over-year to $56.0 million; the TTM figure through Dec 2020 stood at $56.0 million (down 50.88% YoY), while the FY2020 annual figure was $56.0 million, down 50.88% from the prior year.
• Current Deferred Revenue came in at $56.0 million for Q4 2020 at Novartis Ag, down from $114.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $305.0 million in Q4 2017 to a low of $56.0 million in Q4 2020.
• A 4-year average of $177.8 million and a median of $175.0 million in 2018 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue dropped 22.62% in 2018 and slumped 51.69% in 2019, its largest moves.
• Novartis Ag's Current Deferred Revenue stood at $305.0 million in 2017, then dropped by 22.62% to $236.0 million in 2018, then plunged by 51.69% to $114.0 million in 2019, then slumped by 50.88% to $56.0 million in 2020.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $56.0 million, $114.0 million, and $236.0 million for Q4 2020, Q4 2019, and Q4 2018 respectively.

Peer Comparison